Current strategies for infectious disease management

Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program

ABSTRACT

The current morbimortality of serious infections is unacceptable and there is a need to promote the increase in the efficacy of empirical and targeted antimicrobial therapy. This could be achieved by initiatives coming from ASP teams aimed at promoting increased efficacy of antibiotic therapy. In the optimization of the antibiotic therapy there are several critical points in which an adequate timing could achieve benefits in the survival of patients with severe infections: prompt initiation of empirical treatment; de-escalation performance, appropriate targeted treatment; and finally, curtail antibiotic duration.

Keywords: antimicrobial stewardship program, de-escalate, timing, empirical treatment, targeted treatment

INTRODUCTION

The implementing and promotion of the Antimicrobial Stewardship Programs (ASP) [1] during the last decade into the hospitals is a successful history without any doubt. It improved the control of the infections by the clinicians in a new dialectic context which includes experts in Pharmacy and Microbiology in the generation of fully operative expert teams that are able to provide effective clinical interventions in real time to patients with serious infections or produced by difficult-to-treat bacteria. These interventions also include the safe reduction of antibiotic exposition (de-escalation or reduction of the duration of antibiotic therapy). In addition, have improved registration, control and awareness of the challenges of managing these infections, and established a new educational training in these areas. And with the dissemination of all these measures, an evident improvement in the diagnosis, management and treatment of infectious diseases has been achieved.

Nonetheless, it has not been possible to demonstrate a clear improvement in the general prognosis of severe infections [2,3], or in the prevention of the appearance and development of the multidrug-resistant (MDR) bacteria [4,5], which are the two main reasons for the creation and dissemination of the ASP.

In general, the ASPs have not changed the primary objective of the old antibiotic policies, which was to restrict the use of antimicrobials (with focus on the new antimicrobials), with the intention of reducing the selective pressure they exert on the development of microbial resistance to antibiotics. With this type of interventions, it has been possible to reduce costs and improve efficiency on a transient and sectorial basis and, eventually, it has been possible to reduce infections by multidrug-resistant bacteria. But they have not substantially improved the prognosis of serious infections [6].

In order to improve the management of the current high morbidity and mortality due to the serious infections, it may be necessary to modify this emphasis on the overuse of antibiotics. Perhaps, it will be necessary to admit with more determination that we need to increase the efficacy of antibiotic therapy in this stage, based on non-restrictive prescribing of new antibiotics and strategies at the time of diagnosis.

The key points for improving the efficacy of the antibiotic therapy. In our opinion the ASP teams could promote initiatives capable of reducing morbimortality associated with serious infections, as:

1. Early and more precise detection of patients with sepsis/severe infections, poor prognosis and high-risk for MDR bacteria colonization in every/all different care setting. This will require the implementation of optimized programs and strategies for Sepsis detection, ideally using new artificial intelligence technologies and computerized programs.

2. Early and more precise microbiological diagnosis, which would enable faster, deeper and better dissemination of...

Juan Pasquau-Liaño¹
Svetlana Sadyrbaeva-Dolgorova⁰
Sergio Sequera-Arquellada¹
Coral García-Vallecillos¹
Carmen Hidalgo-Tenorio¹

¹Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Nieves, Granada, Spain
²Servicio de Farmacia Hospitalaria, Hospital Universitario Virgen de la Nieves, Granada, Spain

Revista Española de Quimioterapia
doi:10.37201/req/s03.22.2022
individualized microbiological diagnosis and a more operational knowledge of the local pathogenic flora. This would require the incorporation of technical and strategic innovations in microbiological diagnosis.

3. Improved efficacy of antibiotic therapy in both, empirical and targeted treatments; and also the promotion of De-escalation performance and shortening the antibiotic treatment duration [7], which have proven to minimize the development of MDR bacteria. This would require optimized management of new antibiotics agents and new antimicrobial strategies (from antibiotic combination to supplementation with new pharmacological and non-pharmacological products, immunotherapy, phagotherapy, bacterial genetic modification, etc.).

The critical importance of “timing” in these initiatives:

Although in this Review we focus on the importance of timing in the design of the antibiotic strategy, the impact of early diagnosis of Sepsis/Severe Infection and Microbiological Diagnosis is no less important. Therefore, we encourage that all these aspects must be part of any strategy implemented by the ASP teams in order to attempt a reduction in the morbimortality of infections.

In the optimization of the antibiotic therapy there are several critical points in which an adequate timing could achieve benefits in the survival of patients with severe infections. On a direct way: 1) In empirical treatment, and 2) In Targeted Treatment and indirectly, in the choice of the moment for 3) De-escalation performance and 4) to curtail antibiotic duration.

TIMING IN EMPIRICAL TREATMENT

When the severity of the patient with suspected infection is greater, it is essential to start antibiotic treatment immediately. There are many studies correlating delayed initiation of empirical treatment with decreased survival. This is a continuous variable, that allows the formulation of a basic principle in empirical antibiotic therapy, which is “the earlier it is started, the greater the survival achieved” [8]. Based on the available data, severe infections should be treated within the first hours after diagnosis, and never later than 3-4 h.

This is so important that ASP teams should establish surveillance programs to monitor delays in the initiation of antibiotic therapy in patients with severe infections. The measurement of time from patient admission to the hospital to intravenous antibiotic administration (‘door-to-needle time’) is a good indicator of promptness or delay of appropriate empirical treatment, and also includes an assessment of the capability of our health system in the early detection and management of sepsis/severe infection. Thus, these indicators would be an achievable and useful tool for improvement of antibiotic management.

The current criteria for Sepsis have a high specificity in the diagnosis of severe infection. But their sensitivity is lower, and there are many patients with severe infections who do not meet these criteria [9,10]. To improve our ability to detect severe infections accelerating or anticipating the initiation of empirical antibiotic therapy, with focus again in the most vulnerable patients, new criteria must be adopted. These new criteria, although not sufficiently standardized, has proven to have a good predictive capacity [9,10]. For example, the presence of a systemic inflammatory response syndrome (SIRS), high risk of progression and severity (for instance, a Charlson> 3) and high inflammatory markers (such as CRP > 200 mg/L or Procalcitonin > 5-10 ng/mL) can predict severe infection with high probability [9]. Other criteria such as Age > 65 years, vascular catheters, clinical suspicion of endocarditis, NEWS score, predictive models of bacteremia [10] may contribute in this direction, to facilitate an prompt initiation of empirical antibiotic therapy.

Moreover, it would be possible to improve this timeliness if primary care would assume and participate in improving the screening of severe infections in outpatients.

When evaluating these strategies, early initiation of empirical antibiotic therapy in severe infections is a necessary and essential criterion to qualify the treatment as adequate. The other necessary condition is that the choice of antibiotic(s) is appropriate; that is, the antibiotic(s) must be effective (active) against the microorganism causing the infection in each particular patient. Without these two conditions, empirical antibiotic therapy can never be considered adequate. Early and Active is the only choice. Active but Late is associated with worse clinical outcomes, similar to those achieved with Early but Inactive or even Late and Inactive treatment [11,12].

As delay reduces the effectiveness of antibiotic therapy, so does the prescription of antibiotics that are not active against the pathogens causing the infection [13]. Surprisingly, in our current clinical practice, the rate of prescribing empirical antibiotic therapy that is inactive or ineffective is very high (up to 20 and 30%) [13-18]. And the rate would be even worse assuming this new strategic concept that appears in recent leading publications: that in severe infections caused by multidrug-resistant bacteria, two active antibiotics improve the survival rate over that achieved with monotherapy [16,19–21]. Furthermore, in the choice of empirical antimicrobials we should consider several other factors: first of all, the ability to eradicate the infection and its ecological impact, the appropriateness of PK/PD properties to the site of infection, the bacterial inoculum size and the degree of microbial resistance, vulnerability or risk of progression of the patient, and severity of infectious process. Therefore, the optimal empirical antibiotic therapy is considered to be that initiated early, with the highest erradicatory capacity and with the appropriate PK/PD profile, precisely tailored to each individual patient.

For our ASP team, the follow-up of adequate use of empirical treatment has become an important indicator of the use of antimicrobials. And to improve it we have implemented real-time audit programs for all bacteremia and multidrug-resistant isolates in other cultures.
Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a established antimicrobial stewardship program

J. Pasquau
Rev Esp Quimioter 2022; 35 (Suppl. 3): 102-107

The evaluation of antibiotic therapy on the third day is based, accordingly, on clinical evolution data and microbiological results, and should be performed between 24 and 72 h [9].

Depending on the obtained findings, and with the septic focus successfully controlled (in the event that this requires interventions other than antibiotherapy, such as surgery or the removal of infected prosthetic material, the optimization of antibiotherapy may lead to one of these four options, which may overlap (Figure 1).

De-escalation is a key strategy for antibiotherapy optimization. Generally, defined as the reduction of the initial antimicrobial spectrum based on microbiological results, either by switching from a broad-spectrum antimicrobial to a narrow one, or from combination therapy to monotherapy. In other words, it is no more than the choice of the most appropriate treatment against the identified pathogen, in a phase in which, clinical improvement achieved after an antibiotic ‘intensive or induction’ phase, would lead to a certain ‘maintenance phase’, less demanding, in which the reduction or simplification of the antibiotic coverage or potency is possible without negative impact on prognosis, and with ecological advantages (by reducing the duration of exposure to antibiotics and regimens with a critical ecological impact).

Rapid diagnostic microbiological tests and MDR pathogens colonization screenings would allow us to de-escalate from 24-72 h, provided that clinical improvement in the patient has been achieved and empirical antibiotic coverage turns out to be unnecessary [9].

In the absence of microbiological results, de-escalation, in...
cases where the clinical evolution is favorable, should be considered [9,22]. It is based on the idea that most of the overall efficacy of antibiotic therapy is achieved in the first days of treatment, and once a significant clinical improvement has been observed, a practically complete extinction of pathogenic bacterial inoculum has been done, and microbial regrowth and recurrence of symptoms would not occur in patients without severe immunosuppression, uncontrolled septic foci or prothetic material with ineradicable inoculums. And this is more likely to be true the more active or effective the chosen of initial empiric antibiotic therapy was. In addition, the absence of growth of MDR bacteria in cultures (from clinical samples or in colonization screenings) reduces the need to maintain coverage against them.

For our ASP team, it is a priority to promote and monitor that all patients with severe infections should be assessed for the efficacy of antibiotic therapy (based on clinical course and inflammation biomarkers) and microbiological results) between 24 and 72 h after the antibiotic therapy is initiated, allowing an optimization or accuracy of antibiotherapy (Escalation or New empirical rescue therapy, De-escalation -with or without microbiological results, Stopping, if the suspicion of infection disappears).

And this requires economic investments (in the improvement of the healthcare management of severe infections and microbiological diagnosis).

**ANTIBIOTIC TREATMENT DURATION**

Antibiotic efficacy concerns clinical efficacy (Resolution of symptoms), and could be measured by Time to microbiological eradication (or sterilization of positive microbiological cultures), which under experimental or controlled conditions, would be between 2 and 9 days (according to “in vitro” studies, microbiological monitoring studies in patients and biological estimates), depending on the bacterial species (e.g., *Escherichia coli* 2-4 days; *Staphylococcus aureus* 4-9 days), the pharmacological or pharmacodynamic properties of Antibiotics (there is a ‘Pharmacodynamic Hierarchy’ that classifies them according to their activity and eradicatory capacity, and generally places the new antibiotics in the best positions), and the management of these antibiotics (At appropriate doses and based on optimized PK/PD parameters, the time to eradication is reduced; synergistic combination of antibiotics -active against the same bacteria- also decreases time to eradication).

Most of the beneficial effect of appropriate antibiotic therapy accumulates in the first 5–7 days. And if the initial antibiotic therapy is appropriately optimized, even in the first 2-5 days.

This approach is based on multiple published studies which show us, for example, In vitro, the maximum bactericidal effect is completed on the 7th day (ciprofloxacin vs. BGN) [23]. Biological estimates consider that the time to eradication of *E. coli* is 2-4 days, and of *S. aureus* 4-9 days (compared to 6 months for *Mycobacterium tuberculosis*). Computational biology in experimental models has established that microbiological eradication can be achieved in 3.9 days (with intensified initial treatment -front loading-) and 8.7 days (with standard treatment) [24]. In vivo, rapid eradication of the causal pathogen of severe pneumonia (in BAS cultures) can be observed in most patients [25].

Clinical and microbiological biomarkers of infection and inflammation generally improve in 3-5 days when antibiotic therapy is effective [26,27]. There are studies showing significant differences in efficacy, that is, in the time until eradication, between various antibiotics when the comparison is established in those first 2-3 ‘critical’ days of antibiotic therapy (meropenem vs. piperacillin/tazobactam [28]; daptomycin vs. vancomycin [29]). In other studies, differences in efficacy are established based on the reduction of the symptom period (moxifloxacin vs levofloxacin) [30].

In the last 20 years, numerous clinical studies were published demonstrating the similar efficacy and safety of 3- to 8-day vs more prolonged (> 10-14 days) antibiotic treatments [31].

On the other hand, the negative ecological impact of antibiotic therapy begins after the first few days. Disruption of the ecological balance and overgrowth of MDR flora can occur within the first 2-4 days of treatment, but is significantly delayed with intensive initial antibiotic therapy –front loading–, especially if concentration levels of the antibiotic in the septic focus are above the mutations preventive concentration [31–34]. However, when antibiotic therapy is not capable of eradicating the pathogenic microbial inoculum, its prolongation over time greatly increases its ability to select and promote the emergence of resistance. In such a way that the longer the duration of the treatment, the more intense antibiotic activity is required to avoid the emergence of mutations during the treatment [35]. This last point challenges the appropriateness of De-escalation (which reduces antibiotic spectrum when the opposite might be necessary to avoid the emergence of resistance in that scenario. But, in practical terms, the best way to minimize the selection and emergence of resistant microorganisms during antibiotic treatment involves employing a front-loading strategy (early and intensive antibiotic therapy, with the maximum achievable eradicatory capacity) and shortening the duration of treatment [36].

Overall, we could assume that practically all common bacterial infections, including severe cases, could be treated successfully for 5-8 days [31,33]. With the exception of certain conditions where the safety of shortening of the duration is not well demonstrated [31,33]:

a) Absence of a rapid and significant clinical response to initial treatment.

b) Major Immunosuppressed patients (neutropenic, cancer under chemotherapy, etc...).

c) Involving infections that affect tissues or structures difficult to access for antibiotics and that cannot be ‘withdrawn’:

I. Devitalized or abscessified tissues (No control of the septic focus).

II. Bone (osteomyelitis), endocardium (endocarditis), vitreous humor (endophthalmitis)...
III. Prosthetic material, catheters, biofilms...

d) In infections produced by particularly drug-resistant, persistent or latent/quiescent bacteria:

   I. *M. tuberculosis* and other infections of slow chronopathology.

   II. *S. aureus* (especially MRSA).

   III. Non-fermenting gran-negative bacilli, such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, etc.

Finally, to implement all these ideas, the ASP team needs to design specific programs and initiatives that place them in the healthcare surveillance and intervention programs, in the development of the local microbiological map and the local Antibiotherapy Guidelines, and in the educational programs. These should be diffused throughout the hospital, starting with the critical areas and extending to the outpatient setting.

**CONCLUSIONS**

Assuming that the current morbimortality of serious infections is unacceptable, and if we want to contribute to minimize it, we should work on a reorganization of the ASPs that, mainly but not exclusively, promotes an increase in the efficacy of antibiotic therapy and a reduction of its negative ecological impact through improvement of the design of empirical and targeted antibiotherapy (to maximize its efficacy). Numerous studies indicate that improvements can be made in both directions with earlier, more accurate and optimized treatments against the specific infection-causing bacteria in the particular patient, and with the highest possible eradication capacity. The timing of antibiotherapy would be of decisive importance in this design. A very important part of the current and future efficacy of antibiotherapy of severe infections involves the search for earlier antibiotherapies (empirical, targeted and rescue), which should be de-escalated when possible and at the optimum time, and stopped after the shortest time possible with proven efficacy and safety.

**CONFLICT OF INTEREST**

Authors declare no conflict of interest.

**REFERENCES**

1. Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH. Farm Hosp. 2012 Jan;36(1):33.e1-33.e30.

2. Rudd KE, Johnson SC, Agenes KM, Shackelford KA, Tsoi D, Kevljan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–11.

3. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019—results from a systematic review and meta-analysis. Crit Care. 2020;24(1):1-9.

4. Cassini A, Diaz Högberg L, Plachouras D, Quattrrocci A, Hoxha A, Skov Simonsen G. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. 2019

5. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.

6. Davey P, Brown E, Charnari E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews. 2013.

7. Spellberg B. The new antibiotic mantra—“shorter is better”. Vol. 176, JAMA Internal Medicine. American Medical Association; 2016. p. 1254–5.

8. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38(9):1773–85.

9. Mensa J, Barberá J, Ferrer R, Borges M, Rascado P, Maseda E, et al. Recommendations for antibiotic selection for severe nosocomial infections. Rev Esp Quimioter. 2021;34(5):511–24.

10. Julián-Jiménez A, Rubio-Díaz R, Del Castillo JG, Candel González FJ. New predictive models of bacteremia in the emergency department: a step forward. Rev Esp Quimioter. 2022;35(4):344–56.

11. Luna C, Aruj P, Niederman M, Garzón J, Violi D, Prignoni A, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia.

12. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122(1):262–8.

13. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021 Sep;21(9):241–51.

14. Chumbita M, Puerta-Alcalde P, Gudiol C, García-Pouton N, Laporte-Amargós J, Ladino A, et al. Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock. Antimicrob Agents Chemother. 2022 Nov 29;66(2).

15. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empirical treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17(1).

16. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Vieale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a prospective cohort study. Lancet Infect Dis. 2017 Jul 1;17(7):726–34.
Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program

17. Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, et al. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance. Clin Infect Dis. 2020 Mar 3;70(6):1068–74.

18. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015 Dec 6;70(7):2133–43.

19. Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis. Vol. S, Open Forum Infectious Diseases. 2018.

20. Schmid A, Woltersberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis. Sci Rep. 2019 Dec 1;9(1):1–11.

21. Ripa M, Rodríguez-No O, Cardozo C, Naharro-Arellán A, Almela M, Marco F, et al. Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.

22. Sadyrbaeva-Dolgova S, Aznarte-Padial P, Pasquau-Liaño J, Expósito-JL, et al. Follow-up Protected Specimen Brushes to Assess Treatment in Nosocomial Pneumonia. https://doi.org/10.4172/2472-1212.1000103.

23. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073–81.

24. Paterson IK, Hoyle A, Ochola G, Baker-Austin C, Taylor NHG. Optimising antibiotic usage to treat bacterial infections. Sci Rep. 2016;6(November):1–10.

25. Montravers P, Fagon JY, Chastre J, Lecroart M, Dombret MC, Trouillet JL, et al. Follow-up Protected Specimen Brushes to Assess Treatment in Nosocomial Pneumonia. https://doi.org/101164/ajrccm/147138. 2012 Dec 17;147(1):38–44.

26. Vidaur L, Planas K, Sierra R, Dimopoulos G, Ramirez A, Lisboa T, et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest. 2008;133(3):625–32.

27. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med [Internet]. 2003;31(3):676–82.

28. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60(9):1319–25.

29. Schweizer ML, Richardson K, Vaughan Sarrazin MS, Goto M, Livorsi DJ, Nair R, et al. Comparative Effectiveness of Switching to Dap-

tomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections. Clin Infect Dis. 2021 Jan 15;72(Suppl 1):S68–73.

30. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Erratum: Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy (Clinical Infectious Diseases January 1, 2006) 42 (73–81). Clin Infect Dis. 2006;42(9):1350.

31. Pasquau J, de Jesus ES, Sadyrbaeva S, Aznarte P, Hidalgo-Torino C. The Reduction in Duration of Antibiotic Therapy as a Key Element of Antibiotic Stewardship Programs. J Antimicrob Chemother. 2015, 1:1 DOI: 10.4172/2472-1212.1000103.

32. Drlica K, Zhao X. Mutant Selection Window Hypothesis Updated. Clin Infect Dis. 2007 Mar 1;44(5):681–8.

33. Pasquau J, Matesanz M. La Duración del Tratamiento Antibiótico. Rev Esp Quimioter. 2015;28:30–3.

34. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42(3):521–7.

35. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, et al. Impact of Drug Exposure Intensity and Duration of Therapy on the Emergence of Staphylococcus aureus Resistance to a Quinolone Antimicrobial. J Infect Dis [Internet]. 2007 Jun 15;195(12):1818–27.

36. Pasquau J, Sadyrbaeva S, De Jesús SE, Hidalgo-Torino C. The role of antimicrobial stewardship programs in the control of bacterial resistance. Rev Esp Quimioter. 2016;29:47–51.